Zastaprazan is a potassium-competitive acid blocker (P-CAB) utilized for the treatment of acid-related gastrointestinal disorders, including erosive gastroesophageal reflux disease (GERD) and gastric ulcers.… Read more
Zastaprazan is a potassium-competitive acid blocker (P-CAB) utilized for the treatment of acid-related gastrointestinal disorders, including erosive gastroesophageal reflux disease (GERD) and gastric ulcers. By competitively and reversibly inhibiting the H+/K+-ATPase enzyme, it provides potent and rapid suppression of gastric acid secretion. This category includes Zastaprazan and its associated impurities and derivatives, which are essential tools for pharmaceutical laboratories engaged in drug development and rigorous quality control. Analytical chemists rely on these high-quality reference standards to perform accurate impurity profiling and to establish reliable methods for monitoring degradation products during stability testing. Additionally, the availability of specific derivatives and stable isotope labelled compounds supports precise quantification and structural elucidation during the validation of analytical procedures, ensuring regulatory compliance throughout the lifecycle of the drug product.